REXAHN PHARMACEUTICALS, INC. 10-K 12-31-2014

Company

Opus Genetics, Inc.

Filed

March 16, 2015

Period of Report

December 31, 2014

Accession Number

0001140361-15-011969

A 10-K is a company's comprehensive annual report, required by the SEC. It includes audited financial statements, a description of the business, risk factors, and management's discussion of results. Learn more about 10-K filings →